6th May 2015 08:33
LONDON (Alliance News) - Biofrontera AG said Wednesday that it has prepared a scientific publication of positive results from its phase III study for field therapy of actinic keratosis using a combination of its drug ameluz and the BF-RhodoLED lamp.
Field therapy involves treating fields on the face or scalp covered with mild to moderate actinic keratosis - dry scaly patches of skin caused by damage from sun exposure. In the study 90.0% of patients were fully cleared from all actinic keratosis.
The results were first disclosed last October, and are part of Biofrontera's application to get an approval for the combination in the US.
Shares in Biofrontera are untraded in London Wednesday at 175.00 pence. They were up 3.7% in Frankfurt at EUR2.49.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L